The US Food and Drug Administration has approved Gazyva/Gazyvaro (obinutuzumab) for the treatment of adults with primary membranous nephropathy (pMN) at risk of disease progression. pMN is a chronic autoimmune kidney disease characterized by inflammation of the...









International Rett Syndrome Foundation Works to Advance Research and Support Families
CheckRare 7 hours ago